Kidney Medullary Carcinoma clinical trials at UC Davis
1 research study open to eligible people
A Study of Radium-223 Dichloride for Advanced Kidney Cancer Spread to Bones
open to eligible people ages 18 years and up
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone.
Sacramento, California and other locations
Our lead scientists for Kidney Medullary Carcinoma research studies include Mamta Parikh.